• Corpus ID: 184588397

Pharmacological and Computational Approach to Eslicarbazepine: A Short Review

  title={Pharmacological and Computational Approach to Eslicarbazepine: A Short Review},
  author={Nadeem Siddiqui and M S Alam and Sharique Ahmed and Ruhi Ali and Mohammed Faiz Arshad and Waquar Ahsan},
  journal={Biomedical and Pharmacology Journal},
Sepracor Inc. (Nasdaq: SEPR) announced the presentation of Phase III combined clinical results for eslicarbazepine acetate (SEP-0002093 / BIA 2-093) in the treatment of epilepsy at the Ninth Eilat Conference on New Anti-Epileptic Drugs in Spain. The study demonstrates that eslicarbazepine is well tolerated and effective when used as adjunct therapy for adult patients with partial epilepsy with distinctively lesser side effects. The pharmacological and computational properties of eslicarbazepine… 

Figures and Tables from this paper


Pharmacokinetics of eslicarbazepine acetate in patients with moderate hepatic impairment
The pharmacokinetics of ESL was not affected by moderate hepatic impairment, therefore, patients with mild to moderate liver impairment treated with ESL do not require dosage adjustment.
(Aryloxy)aryl semicarbazones and related compounds: a novel class of anticonvulsant agents possessing high activity in the maximal electroshock screen.
Quantitative structure-activity relationships indicated a number of physicochemical parameters which contributed to activity in the MES screen and X-ray crystallography of five compounds suggested the importance of certain interatomic distances and bond angles foractivity in the mouse and rat MES screens.
Antiepileptic drugs
Anticonvulsant and sodium channel-blocking properties of novel 10,11-dihydro-5H-dibenz[b,f]azepine-5-carboxamide derivatives.
It is concluded that acetates (R)-11 and (S)-12 are not simple metabolic precursors of alcohols (R-7 and (s)-6 in rodents but that they possess anticonvulsant and sodium channel-blocking properties in their own right.